Sitemap

J&J To Make Up To Three Billion COVID-19 Vaccines In 2022

More...

Joe Biden Visits Europe On First Overseas Trip As US President

US President Joe Biden embarks on his...

Amazon’s Billionaire Founder Jeff Bezos To Fly To Space Next Month

Amazon’s billionaire founder Jeff Bezos said on...

Production Of Sputnik V Vaccine Starts In Serbia

President of the Republic of Serbia Aleksandar...

World Central Kitchen Kicks Off Across Seven States In India

The non-profit organisation links chefs with Government...

“Smart Serbia” Platform Presented In State Data Centre In Kragujevac

The Office for IT and eGovernment presented today at the State Data Centre in Kragujevac a unique platform “Smart...

EU Digital COVID Certificate

The EU Digital COVID Certificate should facilitate safe free movement inside the EU during the COVID-19 pandemic. The certificate will...

Joe Biden Visits Europe On First Overseas Trip As US President

US President Joe Biden embarks on his first overseas trip on Wednesday where he will meet European partners and...

Nikola Jokic Wins 2020-21 Kia NBA Most Valuable Player Award

The Serbian center becomes the first player to earn the honor as a member of the Denver Nuggets and...

Production Of Sputnik V Vaccine Starts In Serbia

President of the Republic of Serbia Aleksandar Vucic and President of the Russian Federation Vladimir Putin marked tonight, via...

Johnson & Johnson’s chief scientist said the company expects to produce up to 3 billion doses of its COVID-19 vaccine next year, after the European Union approved the one-shot immunization on Thursday.

The company is bringing on three manufacturing plants to produce the key drug substance. It also will have seven plants globally that will handle final production steps and bottling into vials known as fill and finish.

“All these will function together to deliver the 1 billion by the end of the year,” Dr. Paul Stoffels, J&J’s chief scientific officer, said in an interview.

“Next year, we can do more than two billion vaccines, and even up to three if we maximize capacity. With Merck on board, we will be north of 2 billion,” he added, referring to a recent agreement for rival Merck & Co to produce J&J’s vaccine.

Stoffels also said he was confident J&J will be able to deliver a planned 55 million doses to the European Union in the second quarter. An EU official told Reuters this week that J&J had flagged possible supply issues that may complicate these plans.

“We trust that we can deliver close to that amount in Q2,” Stoffels said, adding that final production steps would be the biggest challenge.

“It’s the fill and finish which was the critical part and there we learned we had later access, we started later and had later access to facilities,” he said.

J&J’s shot is the fourth to be endorsed for use in the EU after vaccines from Pfizer/BioNTech, AstraZeneca Plc and Moderna Inc.

Europe is scrambling to get immunization campaigns off the ground after an early supply shortfall from Pfizer, since resolved, and more persistent issues with AstraZeneca.

J&J’s vaccine is expected to be used widely around the globe because of its one-shot convenience and logistical advantage of being shipped and stored at normal refrigerator temperatures. Both the Pfizer/BioNTech and Moderna vaccines require two doses and must be shipped frozen.

Thursday’s approval included authorization in Europe of Maryland-based Emergent Biosolutions Inc, which is making active drug substance for the vaccine.

“Emergent is a very critical supplier. It’s important for both the U.S. and Europe and other parts of the world,” Stoffels said, adding it can deliver enough drug substance for” up to a billion vaccines a year.”

Stoffels said in the United States, the company was only allowed to seek emergency use authorization for one manufacturing plant to produce drug substance.

Initial U.S. doses are being made at the company’s plant in Leiden, the Netherlands. J&J is awaiting U.S. approvals of the Emergent plant for drug substance, and for Catalent Inc, a contract manufacturer that will handle fill and finish from a new manufacturing line in Bloomington, Indiana.

Stoffels said as soon as J&J received U.S. authorization for the vaccine, U.S. regulators started reviewing the company’s additional production plants.

He said early “hiccups” have been resolved and the company expects to deliver on its promise of 100 million doses before the end of June.

In Europe, Stoffels said the company plans to significantly scale up production of its Leiden plant. Additional capacity will come on board likely over the summer, he added.

Indian drugmaker Biological E Ltd will handle both drug substance and fill and finish for J&J’s vaccine. The company’s managing director told Reuters last month that Biological E was looking to contract manufacture roughly 600 million doses ofJ&J’s COVID-19 vaccine a year.

Biological E is in the process of installing and validating equipment in the plant, which Stoffels said he expects to be ready in the second half of this year.

Source: www.reuters.com

Related Articles

EU Digital COVID Certificate

The EU Digital COVID Certificate should facilitate safe free movement inside the EU during the COVID-19 pandemic. The certificate will be available in either digital...

Production Of Sputnik V Vaccine Starts In Serbia

President of the Republic of Serbia Aleksandar Vucic and President of the Russian Federation Vladimir Putin marked tonight, via a video link, the beginning...

The European Commission And Austria Secure COVID-19 Vaccines For The Western Balkans

The European Commission and Austria are announcing today the conclusion of agreements for the delivery of COVID-19 vaccines for the Western Balkans. The 651,000...

Greece Removes Quarantine For Travellers From EU And Other Countries

Greece has lifted its quarantine requirement for travellers from the European Union provided they have been vaccinated or tested negative for COVID-19 over the...

Production Of Sputnik V Launched In Serbia

The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) and Institute of Virology, Vaccines and Sera “Torlak” announce the launch of production of...

Vaccine Passports Are Sreading Across The World Here’s How They Could Work In The US

Vaccine passports are set to become a part of everyday life right across the world as governments race to vaccinate their populations against the...

Skopje Launches Mass Coronavirus Vaccination With Russia’s Sputnik V

Vaccines are available for police officers, Interior Ministry employees, pharmacists, pre-school and school teachers as well as other categories qualified as a critical group Mass...

Serbian Torlak Institute To Get Technology For Sputnik V Vaccine

Serbia’s Torlak Institute on Monday signed a technology transfer agreement with the Russian Direct Investment Fund and the Russian pharmaceuticals company Generium under which...